Xuanwu Hospital Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2015
NCT02504801
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Wei Cuibai

Active Ingredients

Drugs in Phase 4 Trials (2)

budesonide (rhinocort) (1 trial)

memantine (namenda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 4)

Lung Neoplasms (Phase 4)

Postoperative Complications (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 2